Table 2.
Selected clinical studies on the radiotherapy and chemotherapy of ENKL.
| Stage | Protocol | Study | No. | Treatment | Mid. follow-up, month | ORR (%) | CR (%) | OS% | PFS% |
|---|---|---|---|---|---|---|---|---|---|
| I/II | Chemotherapy + RT + chemotherapy | Prospective (78) | 26 | RT with LVP | 27 | 89 | 81 | 89% (2y) | 81% (2y) |
| I/II | Chemotherapy + RT + chemotherapy | Prospective (79) | 27 | RT with GELOX | 27 | 96 | 74 | 86% (2y) | 86% (2y) |
| I/II | RT + chemotherapy | Retrospective (80) | 44 | RT + GDP | 38 | 95 | 89 | 85% (3y) | 77% (3y) |
| I/II | CCRT | Prospective (81) | 27 | RT + DeVIC | 32 | 81 | 77 | 78% (2y) | NA |
| I/II | CCRT | Retrospective (65) | 150 | RT + DeVIC | 67 | 89 | 82 | 72% (5y) | 61% (5y) |
| I/II | CCRT + chemotherapy | Prospective (82) | 30 | CCRT + VIPD | NA | 83 | 80 | 86% (3y) | 85% (3y) |
| I/II | CCRT + chemotherapy | Retrospective (83) | 13 | CCRT + ESHAP | 38 | 100 | 92 | 72%(2y) | 90%(2y) |
| I/II | CCRT + chemotherapy | Prospective (86) | 30 | CCRT + VIDL | 44 | NA | 87 | 73% (5y) | 60% (5y) |
| I/II | CCRT + chemotherapy | Prospective (87) | 66 | CCRT + LVDP | 24 | 86 | 83 | 70% (3y) | 67% (3y) |
| I/II | CCRT + chemotherapy | Prospective (88) | 28 | CCRT + GDP | 38 | 91 | 84 | 88% (3y) | 84% (3y) |
| I/II | CCRT | Retrospective (84) | 12 | RT with MPVIC-P |
– | 100 | 100 | – | – |
| Advanced and rel/ref | Chemotherapy | Prospective (89) | 38 | SMILE | 24 | 79 | 45 | 55% (1y) | 53% (1y) |
| Advanced and rel/ref | Chemotherapy | Prospective (90) | 86 | SMILE | 31 | 81 | 66 | 50% (5y) | 64% (4y) |
| Advanced and rel/ref | Chemotherapy | Retrospective (91) | 13 | MEDA | NA | 77 | 62 | 69% (1y) | 62% (1y) |
| Advanced and rel/ref | Chemotherapy | Retrospective (92) | 24 | P-GEMOX | 28 | 80 | 51 | 39% (3y) | 65% (3y) |
| Advanced and rel/ref | Chemotherapy | Retrospectively (93) | 41 | GDP | 16 | 83 | 42 | 73% (1y) | 55% (1y) |
Mid, median; ORR, overall response rate; CR, complete response; OS, overall survival; PFS, progression-free survival; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; NA, not available; rel/ref, relapsed/refractory.